Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non–Small-Cell Lung Cancer
Author:
Affiliation:
1. University of Texas MD Anderson Cancer Center, Houston, TX
2. Foundation Medicine, Cambridge, MA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/PO.18.00267
Reference33 articles.
1. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
2. ROS1 fusions in Chinese patients with non-small-cell lung cancer
3. ROS1-Rearranged Lung Cancer
4. Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung Cancer
5. ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current treatment and novel insights regarding ROS1‐targeted therapy in malignant tumors;Cancer Medicine;2024-04
2. Progress of non-small-cell lung cancer with ROS1 rearrangement;Frontiers in Molecular Biosciences;2023-12-22
3. ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance;Journal of Drug Targeting;2022-06-14
4. ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date;Current Oncology;2022-01-28
5. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines;Drug Development and Industrial Pharmacy;2021-07-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3